On October 2, 2024, Harpreet Grewal, a Director at Penumbra Inc (PEN, Financial), sold 166 shares of the company, according to a recent SEC Filing. Following this transaction, the insider now owns 8,697 shares of Penumbra Inc. The shares were sold at a price of $190.83, valuing the transaction at approximately $31,698.
Penumbra Inc is a healthcare company focused on innovative medical devices. It specializes in developing and manufacturing tools for vascular and neurovascular therapies.
Over the past year, Harpreet Grewal has sold a total of 1,118 shares of Penumbra Inc and has not made any purchases of the stock. This recent sale is part of a broader trend observed within the company, where there have been 25 insider sells and no insider buys over the past year.
The stock of Penumbra Inc, with a market cap of approximately $7.574 billion, is currently trading at a price-earnings ratio of 573.50. This ratio is significantly higher than both the industry median of 30.29 and the company's historical median.
Despite the high price-earnings ratio, Penumbra Inc is considered significantly undervalued based on the GF Value of $298.53, with a price-to-GF-Value ratio of 0.64. The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This valuation and the insider selling trend might be of interest to investors looking for insights into both the company's stock valuation and insider behaviors.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
